Devonian Health Group, Inc.

Devonian Health Group, Inc.

DVHGF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$13.35M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Devonian Health Group, Inc.Devonian Health Group, Inc.0--86%--

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$13.35 Million
Enterprise Value$12.85 Million
Earnings per Share$-1.76
Beta1.26
Outstanding Shares2,768,506

Return

Return on Equity-86.18%ROE
Return on Assets-69.69%
Return on Invested Capital-158.26%

Valuation & Multiples

P/E Ratio-P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio2.4Price to Book Ratio
Enterprise Value to Revenue4.87
Enterprise Value to EBIT-1.15
Enterprise Value to Net Income-3
Total Debt to Enterprise0.02
Debt to Equity0.03Debt to Equity

Revenue Sources

No data

Next Earnings Call

Expected Date
November 26, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Devonian Health Group, Inc.

8 employees
CEO: Andre Boulet

Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis an...